San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
BioMed Realty Launches New Mobile Application To Provide An Immersive Experience Of Its New Life Science Real Estate Projects
SAN DIEGO, Oct. 13, 2014 /PRNewswire/ — BioMed Realty Trust, Inc. (NYSE: BMR) today became the first life science real estate company to launch a mobile application on the Apple® platform that provides tenants and brokers with an immersive introduction to the company’s four new development opportunities in Boston/Cambridge, San Francisco, San Diego and Seattle.
The new application is now available for free download on iPhones and iPads from Apple’s App Store. This initial beta version of the application provides users with a number of experiences to understand the value and opportunities available at BioMed Realty’s projects at 450 Kendall in Cambridge, i3 in San Diego, Gateway of Pacific in South San Francisco and BioMed Realty Research Center in Seattle.
“We are proud to deliver this innovative tool to support our brokers and tenants, which serves to illustrate the value and experiences of our four development opportunities, each well-located in the heart of a leading research hub and expected to offer fantastic amenities,” said Kent Griffin, President & Chief Operating Officer at BioMed Realty. “We work with some of the most innovative companies in the world, and we strive to provide the right tools to help them visualize how these properties can effectively enable their breakthrough science.”
The BioMed Realty app provides an interactive and comprehensive view of BioMed Realty’s four new life science projects. The app provides for a virtual tour of these state-of-the-art laboratory and office buildings that are or can be developed in these four key markets, including buildings and floor plans, as well as detail on the planned benefits and amenities at these new properties. A must-have app for any life science real estate professional, the BioMed Realty app also allows users to connect directly with the right BioMed Realty people.
Of these four projects, 450 Kendall in Cambridge and BioMed Realty Research Center are under active construction. The i3 and Gateway of the Pacific projects remain in the predevelopment phase.
The full version of the BioMed Realty app will be available later this year which will include all the BioMed Realty properties including the entire Wexford Science + Technology portfolio.
About BioMed Realty Trust
BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 17.2 million rentable square feet. Additional information is available at www.biomedrealty.com. Follow us on Twitter @BioMedRealty.
SOURCE BioMed Realty Trust, Inc.
Long assumed to be destructive to tissues and cells, “free radicals” generated by the cell’s mitochondria—the energy producing structures in the cell—are actually beneficial to healing wounds.
That’s the conclusion of biologists at UC San Diego who discovered that “reactive oxygen species”—chemically reactive molecules containing oxygen, such as peroxides, commonly referred to as free radicals—are necessary for the proper healing of skin wounds in the laboratory roundworm C. elegans.
Philips and Radboud university medical center debut wearable diagnostic prototype for chronic illness at Dreamforce 2014 event
ANDOVER, Mass. and SAN FRANCISCO, Oct. 13, 2014 /PRNewswire/ — Today at the Dreamforce 2014 conference in San Francisco, Royal Philips (NYSE: PHG; AEX: PHIA) and Nijmegen NL-based Radboud university medical center (Radboudumc) announced the debut of a prototype to support patients with chronic obstructive pulmonary disease (COPD). The launch marks the start of joint explorations between Philips and Radboudumc to apply mobile, digital and cloud technologies to improve patient outcomes, care coordination and patient empowerment across the health continuum.
According to the US Centers for Disease Control and Prevention (CDC), 117 million Americans, or nearly one-half of the US adult population, have at least one chronic condition, and one in four adults has two or more. The CDC estimates that caring for patients with chronic conditions accounts for 70% of the annual health care spend in the U.S. In a study released by The World Economic Forum, the global economic impact of the five leading non-communicable diseases – cardiovascular disease, chronic respiratory disease, cancer, diabetes and mental ill-health – could total $47 trillion over the next 20 years.
Management of COPD is challenging and often costly, as the progressive nature of the disease leads many patients to require complicated therapies and frequent hospital readmissions. At the same time, consumers are increasingly looking for new ways to take control of their personal health in order to live healthier and better lives.
“Unlike other wearable solutions recently introduced to the market, this prototype collects more than just wellness data from otherwise healthy people,” said Jeroen Tas, CEO, Healthcare Informatics Solutions and Services, Philips. “We are demonstrating the power of harnessing both clinical and personal health information to better manage chronic disease patients across the health continuum, from healthy living, prevention, diagnosis, treatment, recovery and home care.”
How it works
The wearable diagnostic prototype for COPD patients feeds data collected from patients at home to clinicians through the Philips HealthSuite Digital Platform to two clinical applications currently available on the cloud-based platform – eCareCompanion and eCareCoordinator – which both recently received FDA 510(k) clearance. Once a COPD patient has left the hospital, a wearable diagnostic prototype collects data day and night – including physical activity/inactivity, respiratory indicator, heart rhythm and heart rate variability. That data is then sent via the cloud to the Philips HealthSuite Digital Platform, where it is shared with the appropriate care providers via the eCareCoordinator application, presenting a more complete view of the patient’s illness.
“Together with Philips, we are exploring and developing tools to enable patients to be true partners in their own health care, including Hereismydata™ and thus creating a digital platform for patients to collect data from EMRs as well as personal wearable technology,” said Lucien Engelen, director REshape Innovation Center at Radboud university medical center. “Our collaboration with Philips creates the scale needed for a globalizing sustainable healthcare approach.”
Radboudumc is considered to be one of the most innovative medical centers in Europe focused on digital solutions to enable patient centric care. The innovation center at Radboudumc, part of the network of Singularity University’s Exponential Medicine track in Silicon Valley, is at the forefront of the convergence of technology and patient empowerment, both inside and outside the hospital.
As part of Philips vision for the HealthSuite Digital Platform, the company is working to create a suite of open application programming interfaces (APIs) that can be used by developers to create innovative applications for hospitals and health systems. Visitors to the Philips booth in the Salesforce Customer Showcase at Dreamforce can sign up to learn more about this Developers Toolkit, expected to be available in early 2015.
Members of the press and conference attendees can learn more about the Philips-Radboudumc innovative COPD prototype at the Dreamforce 2014 conference in San Francisco from October 13-16: Demos will be shown at the Dreamforce Industry Health and Life Sciences Showcase (Moscone South/Gateway) and the Customer Showcase areas (Moscone West).
For updates on further platform developments, visit www.philips.com/dreamforce and follow the #DF14 conversation at @PhilipsHealth.
For further information, please contact:
Kathy O’ReillyPhilips(o) 978-659-2638 (mobile) 978-221-8919Kathy.firstname.lastname@example.orgTwitter: @kathyoreilly
Sabine van DeursenPhilips+31 6 15043894Sabine.email@example.comTwitter: @sabinevdeursen
Viola PeulenRadboudumc+31 24 3668799 (mobile) +31 6 55346484Viola.firstname.lastname@example.org
Salesforce and others are trademarks of salesforce.com, inc.
About Royal Philips:Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
About Radboud university medical centerRadboud university medical center is an institute for patient care, research and education & training, located in Nijmegen, the Netherlands. Our mission is to have a significant impact on healthcare. We aim to be a frontrunner in the development of innovative, sustainable and affordable healthcare. By offering excellent quality, participatory and personalized healthcare, operational excellence and sustainable networks. Our almost 10,000 employees and over 3,000 students do their utmost every day to make a positive contribution to the future of healthcare and medical sciences.
Related LinksPhilips Presence at DreamforcePhilips HealthSuite Digital Platform
Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM35608-20141012-1.mp4Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM35608-20141012-2.mp4Infographic – http://photos.prnewswire.com/prnh/20141012/151645-INFOLogo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
SOURCE Royal Philips
SAN DIEGO, Oct. 13, 2014 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent…
Cosmederm Bioscience Announces $50M Investment by UK Investment GroupSAN DIEGO–(BUSINESS WIRE)–Cosmederm Bioscience has announced that UK-based Woodford Investment Management is investing $50 million into Cosmederm Bioscience.We are thrilled about this investment by Woodford Investment Management. It is a testament to our technology platform and…
CytRx Corporation Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
LOS ANGELES, Oct. 13, 2014 /PRNewswire/ –CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has commenced operations at its new discovery laboratory, located in Freiburg, Germany. The new laboratory will conduct discovery…
Biocept, Inc. And Rosetta Genomics Ltd. Collaborate To Evaluate Micrornas From Circulating Tumor Cells
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel, Oct. 13, 2014 (GLOBE NEWSWIRE) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq…
Kite Pharma, Inc. Announces Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
Phase 1 Clinical Trial Highlights: 14 of 20 pediatric or young adult patients (70%) with relapsed or refractory ALL experienced a complete response. 12 of the 20 patients (60%) achieved a minimal…
WESTLAKE VILLAGE, Calif., Oct. 10, 2014 (GLOBE NEWSWIRE) — KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on September 26, 2014, the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase an aggregate of 12,500 shares of the Company…